```
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:30:51 ON 09 NOV 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 14:30:51 ON 09 NOV 2003

FILE 'EMBASE' ENTERED AT 14:30:51 ON 09 NOV 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'USPATFULL' ENTERED AT 14:30:51 ON 09 NOV 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> EGFR(3A)(III)
L1           24 FILE CAPLUS
L2           21 FILE BIOSIS
L3           26 FILE MEDLINE
L4           26 FILE EMBASE
L5           21 FILE USPATFULL

TOTAL FOR ALL FILES
L6          118 EGFR(3A)(III)

=> l6(P)cancer
L7            7 FILE CAPLUS
L8            4 FILE BIOSIS
L9            8 FILE MEDLINE
L10           8 FILE EMBASE
L11           6 FILE USPATFULL

TOTAL FOR ALL FILES
L12          33 L6(P) CANCER

=> l12 and (urine or serum or plasma or csf)
L13           1 FILE CAPLUS
L14           0 FILE BIOSIS
L15           0 FILE MEDLINE
L16           0 FILE EMBASE
L17           6 FILE USPATFULL

TOTAL FOR ALL FILES
L18           7 L12 AND (URINE OR SERUM OR PLASMA OR CSF)

=> dup rem
ENTER L# LIST OR (END):l18
PROCESSING COMPLETED FOR L18
L19            7 DUP REM L18 (0 DUPLICATES REMOVED)

=> d l19 ibib abs total

L19  ANSWER 1 OF 7  USPATFULL on STN
ACCESSION NUMBER:        2003:294379  USPATFULL
TITLE:                   Novel proteins and nucleic acids encoding same
INVENTOR(S):             Alsobrook, John P., II, Madison, CT, UNITED STATES
                         Boldog, Ferenc L., North Haven, CT, UNITED STATES
                         Burgess, Catherine E., Wethersfield, CT, UNITED STATES
                         Casman, Stacie J., North Haven, CT, UNITED STATES
                         Grosse, William M., Branford, CT, UNITED STATES
                         Gusev, Vladimir Y., Madison, CT, UNITED STATES
                         Ji, Weizhen, Branford, CT, UNITED STATES
                         Lepley, Denise M., Branford, CT, UNITED STATES
                         Liu, Xiaohong, Branford, CT, UNITED STATES
                         Mezick, Amanda J., Hamden, CT, UNITED STATES
```

Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Shen, Lei, Hamden, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Szekeres, Edward S., JR., Wallingford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Voss, Edward Z., Wallingford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207394	A1	20031106
APPLICATION INFO.:	US 2002-190115	A1	20020703 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-898994, filed on 3 Jul 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-303168P	20010705 (60)
	US 2002-368996P	20020401 (60)
	US 2002-386816P	20020607 (60)
	US 2000-215854P	20000703 (60)
	US 2000-215856P	20000703 (60)
	US 2000-215902P	20000703 (60)
	US 2000-216585P	20000707 (60)
	US 2000-216586P	20000707 (60)
	US 2000-216722P	20000707 (60)
	US 2000-218622P	20000717 (60)
	US 2000-218992P	20000717 (60)
	US 2000-221285P	20000727 (60)
	US 2001-268734P	20010214 (60)
	US 2001-274260P	20010308 (60)
	US 2001-279856P	20010329 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ivor R. Elrifi, Esq., Mintz, Levin, Cohn, Ferris,, Glovsky and Popeo, P.C., One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
LINE COUNT: 10972

AB Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

L19 ANSWER 2 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2003:158932 USPATFULL
TITLE: Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
INVENTOR(S): Rockwell, Patricia, West Redding, CT, UNITED STATES
Goldstein, Neil I., Maplewood, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003108545	A1	20030612
APPLICATION INFO.:	US 2002-91300	A1	20020304 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-798689, filed on 2 Mar 2001, PENDING Continuation-in-part of Ser. No. US 1999-401163, filed on 22 Sep 1999, GRANTED, Pat. No. US 6365157 Continuation of Ser. No. US 1997-967113, filed on 10 Nov 1997, GRANTED, Pat. No. US 6448077 Continuation of Ser. No. US 1997-779450, filed on 7 Jan 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-706804, filed on 3 Sep 1996, GRANTED, Pat. No. US 5861499 Continuation-in-part of Ser. No. US 1995-476533, filed on 7 Jun 1995, ABANDONED Continuation of Ser. No. US 1994-326552, filed on 20 Oct 1994, GRANTED, Pat. No. US 5840301 Continuation-in-part of Ser. No. US 1994-196041, filed on 10 Feb 1994, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 4558
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation, chemotherapy, and/or an additional receptor antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:748048 CAPLUS
DOCUMENT NUMBER: 135:283947
TITLE: Cancer therapy patient classification based on microarray analysis of gene amplification or deletion using comparative genomic hybridization
INVENTOR(S): Seelig, Steven A.
PATENT ASSIGNEE(S): Vysis, Inc., USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001075160	A1	20011011	WO 2001-US10063	20010329
W: AU, CA, CN, JP, KR				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1268860	A1	20030102	EP 2001-964688	20010329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				

PRIORITY APPLN. INFO.: US 2000-539400 A 20000331
WO 2001-US10063 W 20010329

AB The method of the invention comprises the classification of a **cancer** patient population into various **cancer** therapy groups based on anal. by genomic DNA microarray of multiple gene amplifications or deletions present or absent in the diseased tissue of each patient. In particular, the invention involves patient

classification into one of at least four **cancer** therapy groups based on the microarray anal. of gene amplification or gene deletion at multiple chromosome locations. The invention has the significant clin. advantage of guiding selection of expensive **cancer** adjuvant drugs for use with patients most likely to respond pos. to the individual drug. For example, a genomic DNA microarray simultaneously measuring 59 sep. gene amplifications or gene deletions in diseased tissue can be used to stratify solid tumor **cancer** patients, such as breast **cancer** patients, into at least nine groups: those most likely to respond to (i) anti-HER-2/neu therapy (Herceptin), (ii) anti-**EGFR** therapy (C225 antibody), (**iii**) anti-AKT1 therapy (cis-platin), (iv) anti-PIK3CA therapy, (v) anti-thymidylate synthase therapy (5-fluorouracil), (iv) anti-Topoisomerase II therapy (doxorubicin), (vii) anti-cmyc therapy, (viii) combination of anti-HER-2 therapy and anti-AKT1 therapy, and (ix) combination of anti-EGFR and anti-AKT1 therapy. The invention has the significant clin. advantage of guiding selection of expensive **cancer** adjuvant drugs for use with patients most likely to respond pos. to the individual drug or respond synergistically to a particular combination of adjuvant therapies. The invention has yet another advantage, compared to use of nucleic acid microarrays measuring only gene expression changes in the diseased tissue from normal tissue, of measuring changes in a more stable analyte-chromosomal DNA, than the labile mRNA necessary for gene expression anal.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2001:212420 USPATFULL
TITLE: Immunostimulatory nucleic acids for inducing a Th2 immune response
INVENTOR(S): McCluskie, Michael J., Ottawa, Canada
Davis, Heather L., Ottawa, Canada

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001044416	A1	20011122
APPLICATION INFO.:	US 2001-768012	A1	20010122 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-177461P	20000120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Helen Lockhart, c/o Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210-2211
NUMBER OF CLAIMS: 153
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 3831
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods and products for inducing an immune response using immunostimulatory nucleic acids. In particular the immunostimulatory nucleic acids preferentially induce a Th2 immune response. The invention is useful for treating and preventing disorders associated with a Th1 immune response or for creating a Th2 environment for treating disorders that are sensitive to Th2 immune responses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 5 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2001:63246 USPATFULL
TITLE: Reagent and processes for targeting mutant epidermal growth factor receptors

INVENTOR(S): Wong, Albert J., Philadelphia, PA, United States
Moscatello, David K., Philadelphia, PA, United States
PATENT ASSIGNEE(S): Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6224868	B1	20010501
APPLICATION INFO.:	US 1997-861423		19970521 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-347520, filed on 28 Nov 1994, now abandoned Continuation-in-part of Ser. No. WO 1995-US15401, filed on 28 Nov 1995
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Seidel Gonda, Lavorgna & Monaco, P.C.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Vaccines comprising peptides from a fusion junction present in a mutant human EGF receptor and methods of using these vaccines in the inhibition of tumor formation and enhancement of tumor regression are provided. Cell lines which overexpress a Type III mutant EGF receptor and methods of producing these cell lines are also provided. In addition, antibodies raised against peptides expressed by these cell lines are provided. Further, antisense oligonucleotides targeted to a mutant EGF receptor which decreases expression of a mutant EGF receptor are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 6 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2001:22031 USPATFULL
TITLE: Oligonucleotide inhibition of epidermal growth factor receptor expression
INVENTOR(S): Bennett, C. Frank, Carlsbad, CA, United States
Lipton, Allan, Hershey, PA, United States
Witters, Lois M., York Haven, PA, United States
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)
The Penn State Research Foundation, University Park, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6187585	B1	20010213
APPLICATION INFO.:	US 1999-306876		19990507 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-832658, filed on 4 Apr 1997, now patented, Pat. No. US 5914269
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schwartzman, Robert A.
ASSISTANT EXAMINER: McGarry, Sean
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions and methods are provided for inhibiting the expression of human EGFR. The compositions comprise oligonucleotides complementary to mRNA targeted to nucleic acids encoding EGFR. Methods of using these oligonucleotides for inhibition of EGFR expression and for treatment of diseases such as cancers associated with overexpression

of EGFR are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 7 OF 7 USPATFULL on STN
ACCESSION NUMBER: 1999:69658 USPATFULL
TITLE: Oligonucleotide inhibition of epidermal growth factor receptor expression
INVENTOR(S): Bennett, C. Frank, Carlsbad, CA, United States
Lipton, Allan, Hershey, PA, United States
Witters, Lois M., York Haven, PA, United States
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)
The Penn State Research Foundation, University Park, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5914269		19990622
APPLICATION INFO.:	US 1997-832658		19970404 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: McGarry, Sean
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris, LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 983
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions and methods are provided for inhibiting the expression of human EGFR. The compositions comprise oligonucleotides complementary to mRNA targeted to nucleic acids encoding EGFR. Methods of using these oligonucleotides for inhibition of EGFR expression and for treatment of diseases such as cancers associated with overexpression of EGFR are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file .meeting
'EVENTLINE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.78	30.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-0.65

FILE 'AGRICOLA' ENTERED AT 14:34:55 ON 09 NOV 2003

FILE 'BIOTECHNO' ENTERED AT 14:34:55 ON 09 NOV 2003

FILE 'CONFSCI' ENTERED AT 14:34:55 ON 09 NOV 2003

FILE 'HEALSAFE' ENTERED AT 14:34:55 ON 09 NOV 2003

```
FILE 'IMSDRUGCONF' ENTERED AT 14:34:55 ON 09 NOV 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 14:34:55 ON 09 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)


FILE 'MEDICONF' ENTERED AT 14:34:55 ON 09 NOV 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 14:34:55 ON 09 NOV 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

=> EGFRvIII and cancer and (serum, plasma, csf, or urine)
L20             0 FILE AGRICOLA
L21             0 FILE BIOTECHNO
L22             0 FILE CONFSCI
L23             0 FILE HEALSAFE
L24             0 FILE IMSDRUGCONF
L25             0 FILE LIFESCI
L26             0 FILE MEDICONF
L27             0 FILE PASCAL

TOTAL FOR ALL FILES
L28             0 EGFRVIII AND CANCER AND (SERUM, PLASMA, CSF, OR URINE)

=>  EGFRvIII
L29             0 FILE AGRICOLA
L30            63 FILE BIOTECHNO
L31             0 FILE CONFSCI
L32             0 FILE HEALSAFE
L33             0 FILE IMSDRUGCONF
L34            37 FILE LIFESCI
L35             0 FILE MEDICONF
L36            44 FILE PASCAL

TOTAL FOR ALL FILES
L37           144 EGFRVIII

=> l37 and cancer
L38             0 FILE AGRICOLA
L39            40 FILE BIOTECHNO
L40             0 FILE CONFSCI
L41             0 FILE HEALSAFE
L42             0 FILE IMSDRUGCONF
L43            16 FILE LIFESCI
L44             0 FILE MEDICONF
L45            16 FILE PASCAL

TOTAL FOR ALL FILES
L46            72 L37 AND CANCER

=> l46 and ELISA
L47             0 FILE AGRICOLA
L48             3 FILE BIOTECHNO
L49             0 FILE CONFSCI
L50             0 FILE HEALSAFE
L51             0 FILE IMSDRUGCONF
L52             1 FILE LIFESCI
L53             0 FILE MEDICONF
```

L54 2 FILE PASCAL

TOTAL FOR ALL FILES
L55 6 L46 AND ELISA

=> dup rem
ENTER L# LIST OR (END):155
DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF, MEDICONF'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L55
L56 5 DUP REM L55 (1 DUPLICATE REMOVED)

=> d l56 ibib abs total

L56 ANSWER 1 OF 5 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN
ACCESSION NUMBER: 2003:37102750 BIOTECHNO
TITLE: Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses
AUTHOR: Liu Z.; Panousis C.; Smyth F.E.; Murphy R.; Wirth V.; Cartwright G.; Johns T.G.; Scott A.M.
CORPORATE SOURCE: Dr. Z. Liu, Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Austin/Repatriation Medical Centre, 145-163 Studley Road, Heidelberg, Vic. 3084, Australia.
E-mail: zhanqi.liu@ludwig.edu.au
SOURCE: Hybridoma and Hybridomics, (2003), 22/4 (219-228), 31 reference(s)
CODEN: HHYYBF ISSN: 1536-8599
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2003:37102750 BIOTECHNO
AB The chimeric monoclonal antibody ch806 specifically targets the tumor-associated mutant epidermal growth factor receptor (de 2-7EGFR or **EGFRVIII**) and is currently under investigation for its potential use in **cancer** therapy. The humanised monoclonal antibody hu3S193 specifically targets the Lewis Y epithelial antigen and is currently in Phase I clinical trials in patients with advanced breast, colon, and ovarian carcinomas. To assist the clinical evaluation of ch806 and hu3S193, laboratory assays are required to monitor their serum pharmacokinetics and quantitate any immune responses to the antibodies. Mice immunized with ch806 or hu3S193 were used to generate hybridomas producing antibodies with specific binding to ch806 or hu3S193 and competitive for antigen binding. These anti-idiotype antibodies (designated Ludwig Melbourne Hybridomas, LMH) were investigated as reagents suitable for use as positive controls for HAHA or HACA analyses and for measuring hu3S193 or ch806 in human serum. Anti-idiotypes with the ability to concurrently bind two target antibody molecules were identified, which enabled the development of highly reproducible, sensitive, specific **ELISA** assays for determining serum concentrations of hu3S193 and ch806 with a 3 ng/mL limit of quantitation using LMH-3 and LMH-12, respectively. BIAcore analyses determined high apparent binding affinity for both idiotypes: LMH-3 binding immobilized hu3S193, Ka = 4.76 x 10.sup.8 M.sup.-.sup.1; LMH-12 binding immobilised ch806, Ka = 1.74 x 10.sup.9 M.sup.-.sup.1. Establishment of HAHA or HACA analysis of sera samples using BIAcore was possible using LMH-3 and LMH-12 as positive controls for quantitation of immune responses to hu3S193 or ch806 in patient sera. These anti-idiotypes could also be used to study the penetrance and binding of ch806 or hu3S193 to tumor cells through immunohistochemical analysis of tumor biopsies. The generation of anti-idiotype antibodies capable of concurrently binding a target antibody on each variable domain provides reagents with high sensitivity for the assessment of safety and pharmacokinetic profiles of target

antibodies administered clinically.

L56 ANSWER 2 OF 5 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 2002-0194513 PASCAL
COPYRIGHT NOTICE: Copyright .COPYRGT. 2002 INIST-CNRS. All rights reserved.
TITLE (IN ENGLISH): Generation of anti-idiotypic reagents in the **EGFRvIII** tumor-associated antigen system
AUTHOR: WIKSTRAND Carol J.; COLE Vanessa R.; CROTTY Laura E.; SAMPSON John H.; BIGNER Darell D.
CORPORATE SOURCE: Department of Pathology, Box 3156, Medical Center, Duke University Medical Center, Durham, NC 27710, United States; Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
SOURCE: Cancer immunology and immunotherapy, (2002), 50(12), 639-652, 39 refs.
ISSN: 0340-7004 CODEN: CIIMDN
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: Germany, Federal Republic of
LANGUAGE: English
AVAILABILITY: INIST-16198, 354000102316040010
AN 2002-0194513 PASCAL
CP Copyright .COPYRGT. 2002 INIST-CNRS. All rights reserved.
AB The use of anti-idiotype (anti-id) vaccines for immunotherapy of human **cancers** is attractive, as immunization with true anti-id reagents (Ab2.beta.) has been shown to induce both cellular and humoral immunity, frequently when the original antigen does not, or when a state of anergy to the self-expressed tumor-associated antigen exists. The aim of this study was to investigate the potential of an anti-id vaccine approach to the glioma-associated antigen epidermal growth factor receptor variant III (**EGFRvIII**) for human clinical trials. By using conventional methodology, seven rat mAbs specific for the binding site of the murine anti-**EGFRvIII**-specific mAb Y10, as defined by the ability to inhibit the binding of mAb Y10 to **EGFRvIII** expressed on cells or as purified protein, were generated, and a subset (3/7) was found to be true Ab2.beta., as defined by the ability to induce the formation of antibody directed against **EGFRvIII** in two species (mouse and rabbit) when used as immunogen. The ability of these three Ab2.beta. to elicit a protective anti-tumor response when used as a vaccine in the syngeneic, subcutaneous C57B1/ 6-B16mseEGFRvIII tumor model was investigated. Following vaccination with one Ab2.beta. mAb (2C7), 6/20 mice failed to develop tumor upon challenge, and 3/20 mice with outgrowing tumors exhibited dramatic regression of incipient tumors. Vaccination with a second mAb (5G8) resulted in one tumor-free survivor and one tumor regressor; vaccination with the third Ab2.beta. mAb (7D3) did not confer protection, but did significantly increase the latency period until tumor outgrowth in all vaccinated recipients. The ability of Ab2.beta. mAb 2C7 to induce an anti-**EGFRvIII** response in non-human primates was investigated by using the saponin adjuvant approved for human clinical trial, QS-21. Three of three macaques produced anti-**EGFRvIII** titers, as detected on **EGFRvIII** -expressing cells by both **ELISA** and fluorescence-activated cytometric analysis, following six immunizations with Ab2.beta. mAb 2C7 and QS-21. The results obtained confirm that an anti-id response in the **EGFRvIII** antigen system can be induced in rodents, rabbits, and non-human primates, and it may prove a useful adjunct to immunotherapeutic approaches to **EGFRvIII**-positive gliomas, breast carcinomas, and non-small-cell lung tumors.

L56 ANSWER 3 OF 5 LIFESCI COPYRIGHT 2003 CSA on STN
ACCESSION NUMBER: 2003:30690 LIFESCI
TITLE: Generation of anti-idiotypic reagents in the

EGFRvIII tumor-associated antigen system

AUTHOR: Wikstrand, C.J.; Cole, V.R.; Crotty, L.E.; Sampson, J.H.; Bigner, D.D.

CORPORATE SOURCE: Department of Pathology, Box 3156, Medical Center, Duke University Medical Center, Durham, NC 27710, USA; E-mail: wikst001@mc.duke.edu

SOURCE: Cancer Immunology, Immunotherapy [Cancer Immunol., Immunother.], (20020200) vol. 50, no. 12, pp. 636-652. ISSN: 0340-7004.

DOCUMENT TYPE: Journal

FILE SEGMENT: F

LANGUAGE: English

SUMMARY LANGUAGE: English

AB The use of anti-idiotype (anti-id) vaccines for immunotherapy of human **cancers** is attractive, as immunization with true anti-id reagents (Ab2 beta) has been shown to induce both cellular and humoral immunity, frequently when the original antigen does not, or when a state of anergy to the self-expressed tumor-associated antigen exists. The aim of this study was to investigate the potential of an anti-id vaccine approach to the glioma-associated antigen epidermal growth factor receptor variant III (**EGFRvIII**) for human clinical trials. By using conventional methodology, seven rat mAbs specific for the binding site of the murine anti-**EGFRvIII**-specific mAb Y10, as defined by the ability to inhibit the binding of mAb Y10 to **EGFRvIII** expressed on cells or as purified protein, were generated, and a subset (3/7) was found to be true Ab2 beta , as defined by the ability to induce the formation of antibody directed against **EGFRvIII** in two species (mouse and rabbit) when used as immunogen. The ability of these three Ab2 beta to elicit a protective anti-tumor response when used as a vaccine in the syngeneic, subcutaneous C57B1/6-B16mseEGFRvIII tumor model was investigated. Following vaccination with one Ab2 beta mAb (2C7), 6/20 mice failed to develop tumor upon challenge, and 3/20 mice with outgrowing tumors exhibited dramatic regression of incipient tumors. Vaccination with a second mAb (5G8) resulted in one tumor-free survivor and one tumor regressor; vaccination with the third Ab2 beta mAb (7D3) did not confer protection, but did significantly increase the latency period until tumor outgrowth in all vaccinated recipients. The ability of Ab2 beta mAb 2C7 to induce an anti-**EGFRvIII** response in non-human primates was investigated by using the saponin adjuvant approved for human clinical trial, QS-21. Three of three macaques produced anti-**EGFRvIII** titers, as detected on **EGFRvIII**-expressing cells by both **ELISA** and fluorescence-activated cytometric analysis, following six immunizations with Ab2 beta mAb 2C7 and QS-21. The results obtained confirm that an anti-id response in the **EGFRvIII** antigen system can be induced in rodents, rabbits, and non-human primates, and it may prove a useful adjunct to immunotherapeutic approaches to **EGFRvIII** -positive gliomas, breast carcinomas, and non-small-cell lung tumors.

L56 ANSWER 4 OF 5 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN

ACCESSION NUMBER: 2001:34146569 BIOTECHNO

TITLE: Generation of anti-idiotypic reagents in the **EGFRvIII** tumor-associated antigen system

AUTHOR: Wikstrand C.J.; Cole V.R.; Crotty L.E.; Sampson J.H.; Bigner D.D.

CORPORATE SOURCE: C.J. Wikstrand, Department of Pathology, Box 3156, Duke University Medical Center, Durham, NC 27710, United States.
E-mail: wikst001@mc.duke.edu

SOURCE: Cancer Immunology, Immunotherapy, (2001), 50/12 (639-652), 39 reference(s)
CODEN: CIIMDN ISSN: 0340-7004

DOCUMENT TYPE: Journal; Article

COUNTRY: Germany, Federal Republic of

LANGUAGE: English

SUMMARY LANGUAGE: English
AN 2001:34146569 BIOTECHNO
AB The use of anti-idiotype (anti-id) vaccines for immunotherapy of human **cancers** is attractive, as immunization with true anti-id reagents (Ab2.beta.) has been shown to induce both cellular and humoral immunity, frequently when the original antigen does not, or when a state of anergy to the self-expressed tumor-associated antigen exists. The aim of this study was to investigate the potential of an anti-id vaccine approach to the glioma-associated antigen epidermal growth factor receptor variant III (**EGFRvIII**) for human clinical trials. By using conventional methodology, seven rat mAbs specific for the binding site of the murine anti-**EGFRvIII**-specific mAb Y10, as defined by the ability to inhibit the binding of mAb Y10 to **EGFRvIII** expressed on cells or as purified protein, were generated, and a subset (3/7) was found to be true Ab2.beta., as defined by the ability to induce the formation of antibody directed against **EGFRvIII** in two species (mouse and rabbit) when used as immunogen. The ability of these three Ab2.beta. to elicit a protective anti-tumor response when used as a vaccine in the syngeneic, subcutaneous C57Bl/6-B16mseEGFRvIII tumor model was investigated. Following vaccination with one Ab2.beta. mAb (2C7), 6/20 mice failed to develop tumor upon challenge, and 3/20 mice with outgrowing tumors exhibited dramatic regression of incipient tumors. Vaccination with a second mAb (5G8) resulted in one tumor-free survivor and one tumor regressor; vaccination with the third Ab2.beta. mAb (7D3) did not confer protection, but did significantly increase the latency period until tumor outgrowth in all vaccinated recipients. The ability of Ab2.beta. mAb 2C7 to induce an anti-**EGFRvIII** response in non-human primates was investigated by using the saponin adjuvant approved for human clinical trial, QS-21. Three of three macaques produced anti-**EGFRvIII** titers, as detected on **EGFRvIII** -expressing cells by both **ELISA** and fluorescence-activated cytometric analysis, following six immunizations with Ab2.beta. mAb 2C7 and QS-21. The results obtained confirm that an anti-id response in the **EGFRvIII** antigen system can be induced in rodents, rabbits, and non-human primates, and it may prove a useful adjunct to immunotherapeutic approaches to **EGFRvIII**-positive gliomas, breast carcinomas, and non-small-cell lung tumors.

L56 ANSWER 5 OF 5 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN DUPLICATE
ACCESSION NUMBER: 1995:25216942 BIOTECHNO
TITLE: Monoclonal antibodies against **EGFRvIII** are tumor specific and react with breast and lung carcinomas and malignant gliomas
AUTHOR: Wikstrand C.J.; Hale L.P.; Batra S.K.; Hill M.L.; Humphrey P.A.; Kurpad S.N.; McLendon R.E.; Moscatello D.; Pegram C.N.; Reist C.J.; Traweek S.T.; Wong A.J.; Zalutsky M.R.; Bigner D.D.
CORPORATE SOURCE: Pathology Department, Duke University Medical Center, Box 3156,Durham, NC 27710, United States.
SOURCE: Cancer Research, (1995), 55/14 (3140-3148)
CODEN: CNREA8 ISSN: 0008-5472
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 1995:25216942 BIOTECHNO
AB Despite molecular biological advances in understanding human **cancers**, translation into therapy has been less forthcoming; targeting neoplastic cells still requires that tumor-specific markers, preferably those on the cell surface, be identified. The epidermal growth factor receptor (EGFR) exists in a deletion-mutant form, **EGFRvIII** , which has been identified by genetic and immunological means in a subset of gliomas and non-small cell lung carcinomas. Specific polyvalent

antisera to the extracellular portion of the variant were readily induced, but immunization using a synthetic linear peptide representing the unique **EGFRvIII** primary sequence has been unsuccessful in mice or macaques. We report here five specific monoclonal antibodies (mAbs) developed through long-term immunization protocols using the **EGFRvIII**-specific synthetic peptide and the intact variant in different formats that maintained secondary and tertiary conformation. These mAbs identify the **EGFRvIII** on the cell surface with relatively high affinity (K(A) range, 0.13 to 2.5 x 10.sup.9 M.sup.-.sup.1) by live cell Scatchard analysis. These mAbs are specific fur **EGFRvIII** as determined by RIA, **ELISA**, Western blot, analytical flow cytometry, autophosphorylation, and immunohistochemistry. Isolating specific mAbs enabled us tn analyze normal and neoplastic human tissue and establish that **EGFRvIII** is truly tumor specific for subsets of breast carcinomas and for previously reported non-small cell lung carcinomas and gliomas. Also, this receptor is not expressed by any normal human tissues thus far examined, including elements of the peripheral, central nervous, and lymphoid systems. With mAbs, we identified a higher incidence of **EGFRvIII** positivity in gliomas than previously described and identified an **EGFRvIII**- positive subset of breast tumors; also, we observed that the **EGFRvIII** epitope is not expressed in normal tissues, and we demonstrated the localizing and therapeutic potential of the mAbs for tumors expressing this epitope. Our observations strongly warrant development of this mAb-antigen system as therapy for breast, lung, and central nervous system tumors.

```
=> file .chemistry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      14.08      45.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -0.65

FILE 'CAPLUS' ENTERED AT 14:39:01 ON 09 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 14:39:01 ON 09 NOV 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 14:39:01 ON 09 NOV 2003
Compendex Compilation and Indexing (C) 2003
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 14:39:01 ON 09 NOV 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 14:39:01 ON 09 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 14:39:01 ON 09 NOV 2003
COPYRIGHT (c) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 14:39:01 ON 09 NOV 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> EGFRVIII AND CANCER
L57          37 FILE CAPLUS
```

```
L58          40 FILE BIOTECHNO
L59           0 FILE COMPENDEX
L60           0 FILE ANABSTR
L61           0 FILE CERAB
L62           0 FILE METADEX
L63          52 FILE USPATFULL

TOTAL FOR ALL FILES
L64         129 EGFRVIII AND CANCER

=> l64 and ELISA
L65           4 FILE CAPLUS
L66           3 FILE BIOTECHNO
L67           0 FILE COMPENDEX
L68           0 FILE ANABSTR
L69           0 FILE CERAB
L70           0 FILE METADEX
L71          41 FILE USPATFULL

TOTAL FOR ALL FILES
L72          48 L64 AND ELISA

=> l72 and (serum or plasma or csf or urine)
L73           2 FILE CAPLUS
L74           1 FILE BIOTECHNO
L75           0 FILE COMPENDEX
L76           0 FILE ANABSTR
L77           0 FILE CERAB
L78           0 FILE METADEX
L79          41 FILE USPATFULL

TOTAL FOR ALL FILES
L80          44 L72 AND (SERUM OR PLASMA OR CSF OR URINE)

=> dup rem
ENTER L# LIST OR (END):l80
PROCESSING COMPLETED FOR L80
L81           43 DUP REM L80 (1 DUPLICATE REMOVED)

=> l81 and py<2002
L82           2 S L81
L83           1 FILE CAPLUS
L84           0 S L81
L85           0 FILE BIOTECHNO
L86           0 S L81
L87           0 FILE COMPENDEX
L88           0 S L81
L89           0 FILE ANABSTR
L90           0 S L81
L91           0 FILE CERAB
L92           0 S L81
L93           0 FILE METADEX
L94          41 S L81
L95          13 FILE USPATFULL

TOTAL FOR ALL FILES
L96          14 L81 AND PY<2002

=> dup rem
ENTER L# LIST OR (END):l96
PROCESSING COMPLETED FOR L96
L97           14 DUP REM L96 (0 DUPLICATES REMOVED)

=> d l97 ibib abs total
```

L97 ANSWER 1 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2002:297455 USPATFULL
TITLE: Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells
INVENTOR(S): Nelson, Edward L., Eldersburg, MD, United States
Strobl, Susan L, Hagerstown, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6479286	B1	20021112	
	WO 9853048		19991126	<--
APPLICATION INFO.:	US 2000-424173		20000605	(9)
	WO 1999-US9810311		19990520	
			20000605	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-47348P	19970521 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Ketter, James
ASSISTANT EXAMINER: Li, Q Janice
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of generating IL-3 expanded populations of monocytes and differentiating the cells into dendritic cells are provided. The methods include use of the dendritic cells to activate T-cells, in vitro and in vivo, and for ex vivo and other therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:693382 CAPLUS
DOCUMENT NUMBER: 135:256132
TITLE: Sensitive detection of wild-type and mutant EGFR by specific **ELISA** assays in any biological sample
INVENTOR(S): Wong, Albert J.; Leitzel, Kim E.; Moscatello, David K.; Lipton, Allan
PATENT ASSIGNEE(S): Thomas Jefferson University, USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068711	A1	20010920	WO 2001-US7766	20010312 <--
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2001046686	A1	20011129	US 2001-803854	20010312 <--

EP 1276771 A1 20030122 EP 2001-918548 20010312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR
PRIORITY APPLN. INFO.: US 2000-188424P P 20000310
WO 2001-US7766 W 20010312
AB The present invention generally relates to a method of detecting type III mutant EGF receptor (**EGFRvIII**) in biol. samples, a method of detecting **cancers** and other diseases in biol. samples, and to a method of assessing treatment and selecting therapy for **cancer** patients.
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L97 ANSWER 3 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2001:218198 USPATFULL
TITLE: Sensitive detection of wild-type and mutant EGFR by specific **ELISA** assays in any biological sample
INVENTOR(S): Wong, Albert J., Philadelphia, PA, United States
Leitzel, Kim E., Hummelstown, PA, United States
Moscatello, David K., Philadelphia, PA, United States
Lipton, Allan, Hershey, PA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001046686	A1	20011129	<--
APPLICATION INFO.:	US 2001-803854	A1	20010312 (9)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-188424P	20000310 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS JEFFERSON UNIVERSITY, INTELLECTUAL PROPERTY DIVISION, 1020 WALNUT STREET, SUITE 620, PHILADELPHIA, PA, 19107
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention generally relates a method of detecting type III mutant EGF receptor (**EGFRvIII**) in biological samples, a method of detecting **cancers** and other diseases in biological samples, and to a method of assessing treatment and selecting therapy for **cancer** patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 4 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2001:152725 USPATFULL
TITLE: Fusion proteins for protein delivery
INVENTOR(S): Davis, Pamela B., Cleveland Heights, OH, United States
Ferkol, Thomas, Concord, OH, United States
Eckman, Elizabeth, Ponte Vedra Beach, FL, United States
Schreiber, John, Gates Mills, OH, United States
Luk, John M., South Horizons, Hong Kong
PATENT ASSIGNEE(S): Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6287817	B1	20010911	<--
APPLICATION INFO.:	US 2000-559393		20000426 (9)	

RELATED APPLN. INFO.: Division of Ser. No. US 1997-957333, filed on 24 Oct 1997, now patented, Pat. No. US 6072041
Continuation-in-part of Ser. No. US 1996-655705, filed on 3 Jun 1996, now patented, Pat. No. US 5972900
Continuation-in-part of Ser. No. US 1996-656906, filed on 3 Jun 1996, now patented, Pat. No. US 5972901
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Park, Hankyel T.
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A protein conjugate consisting of antibody directed at the pIgR and A.sub.1 AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 5 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2001:121518 USPATFULL
TITLE: Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
INVENTOR(S): Schneck, Jonathan, Silver Spring, MD, United States
Pardoll, Drew, Brookeville, MD, United States
O'Herrin, Sean, Baltimore, MD, United States
Slansky, Jill, Baltimore, MD, United States
Greten, Tim, Baltimore, MD, United States
PATENT ASSIGNEE(S): The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6268411	B1	20010731	<--
APPLICATION INFO.:	US 1998-150622		19980910	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Banner & wittcoff, Ltd.
NUMBER OF CLAIMS: 104
EXEMPLARY CLAIM: 1,69
NUMBER OF DRAWINGS: 31 Drawing Figure(s); 24 Drawing Page(s)
LINE COUNT: 1814
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the .sup.pep MHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors.

.sup.pep MHC/Ig complexes are also useful in modulating effector functions of antigen-specific T cells. These .sup.pep MHC/Ig complexes are useful for studying TCR/MHC interactions and lymphocyte tracking and

have uses as specific regulators of immune responses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 6 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2001:112055 USPATFULL
TITLE: Bifunctional molecules for delivery of therapeutics
INVENTOR(S): Davis, Pamela B., Cleveland heights, OH, United States
Ferkol, Jr., Thomas W., Concord, OH, United States
Eckman, Elizabeth, Ponte Vedra Beach, FL, United States
PATENT ASSIGNEE(S): Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6261787	B1	20010717	<--
APPLICATION INFO.:	US 1999-264032		19990308 (9)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-957333, filed on 24 Oct 1997, now patented, Pat. No. US 6072041
Continuation-in-part of Ser. No. US 1996-655705, filed on 3 Jun 1996, now patented, Pat. No. US 5972900
Continuation-in-part of Ser. No. US 1996-656906, filed on 3 Jun 1996, now patented, Pat. No. US 5972901
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Park, Hankyel T.
LEGAL REPRESENTATIVE: Banner & Witcoff LTD
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 1650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A bifunctional molecule consisting of a therapeutic molecule and a ligand which specifically binds a transcytotic receptor can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides the ability to deliver a therapeutic molecule directly to the apical surface of the epithelium, by targeting the transcytotic receptor with an appropriate ligand. Thus, the highest concentration of the therapeutic molecule will be at the apical surface, where it can have the greatest therapeutic effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 7 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2001:75367 USPATFULL
TITLE: Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
INVENTOR(S): Paul, Sudhir, 7900 Cambridge, 14-1G, Houston, TX, United States 77054
Gololobov, Gennady, 5500 N. Braeswood, Apt. 259, Houston, TX, United States 77096
Smith, Larry J., 7824 Jackson St., Omaha, NE, United States 68114

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6235714	B1	20010522	<--
APPLICATION INFO.:	US 1998-46373		19980323 (9)	

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huff, Sheela
LEGAL REPRESENTATIVE: Dann, Dorfman, Herrell and Skillman
NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 3997
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens associated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 8 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2001:63246 USPATFULL
TITLE: Reagent and processes for targeting mutant epidermal growth factor receptors
INVENTOR(S): Wong, Albert J., Philadelphia, PA, United States
Moscatello, David K., Philadelphia, PA, United States
PATENT ASSIGNEE(S): Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6224868	B1	20010501	<--
APPLICATION INFO.:	US 1997-861423		19970521 (8)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-347520, filed on 28 Nov 1994, now abandoned Continuation-in-part of Ser. No. WO 1995-US15401, filed on 28 Nov 1995
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Seidel Gonda, Lavorgna & Monaco, P.C.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Vaccines comprising peptides from a fusion junction present in a mutant human EGF receptor and methods of using these vaccines in the inhibition of tumor formation and enhancement of tumor regression are provided. Cell lines which overexpress a Type III mutant EGF receptor and methods of producing these cell lines are also provided. In addition, antibodies raised against peptides expressed by these cell lines are provided. Further, antisense oligonucleotides targeted to a mutant EGF receptor which decreases expression of a mutant EGF receptor are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 9 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2000:134582 USPATFULL
TITLE: Epidermal growth factor receptor antibodies
INVENTOR(S): Wels, Winfried S., Emmendingen, Germany, Federal Republic of
Schmidt, Mathias, Freiburg, Germany, Federal Republic of
Vakalopoulou, Evangelia, Berlin, Germany, Federal Republic of
Schneider, Douglas W., Lafayette, CA, United States
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6129915		20001010	<--
APPLICATION INFO.:	US 1999-296595		19990423 (9)	

RELATED APPLN. INFO.: Division of Ser. No. US 1997-800198, filed on 13 Feb 1997, now patented, Pat. No. US 5942602
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huff, Sheela
ASSISTANT EXAMINER: Helms, Larry R.
LEGAL REPRESENTATIVE: Millen, White, Zelano, & Branigan, P.C.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is related to single and double chain antibodies to EGF receptor. The invention also relates to toxin conjugates of such antibodies. These antibodies are useful for treating and diagnosing the status of pathological conditions such as **cancer** and cellular hyper proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 10 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2000:131598 USPATFULL
TITLE: Method for diagnosing glioma associated with structural alterations of the EGF receptor gene in human tumors
INVENTOR(S): Vogelstein, Bert, Baltimore, MD, United States
Bigner, Darell, Mebane, NC, United States
PATENT ASSIGNEE(S): The Johns Hopkins University, United States (U.S. corporation)
Duke University, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6127126		20001003	<--
APPLICATION INFO.:	US 1999-264723		19990309 (9)	

RELATED APPLN. INFO.: Division of Ser. No. US 1995-479808, filed on 7 Jun 1995, now patented, Pat. No. US 5981725 which is a continuation-in-part of Ser. No. US 1992-896909, filed on 11 Jun 1992, now abandoned which is a continuation of Ser. No. US 1990-531410, filed on 1 Jun 1990 which is a continuation-in-part of Ser. No. US 1989-404226, filed on 8 Sep 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Srivastava, Devah
LEGAL REPRESENTATIVE: Banner & Wifcoff, Ltd.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Figure(s); 30 Drawing Page(s)
LINE COUNT: 2152
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 11 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2000:70969 USPATFULL
TITLE: Fusion proteins for protein delivery
INVENTOR(S): Davis, Pamela B., Cleveland Heights, OH, United States

Ferkol, Thomas, Concord, OH, United States
Eckman, Elizabeth, Ponte Vedra Beach, FL, United States
Schreiber, John, Gates Mills, OH, United States
Luk, John M., South Horizons, Hong Kong
PATENT ASSIGNEE(S): Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6072041		20000606	<--
APPLICATION INFO.:	US 1997-957333		19971024	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-655705, filed on 3 Jun 1996 And Ser. No. US 1996-656906, filed on 3 Jun 1996
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Park, Hankyel
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1210
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A protein conjugate consisting of antibody directed at the pIgR and A.sub.1 AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 12 OF 14 USPATFULL on STN
ACCESSION NUMBER: 1999:142132 USPATFULL
TITLE: Structural alterations of the EGF receptor gene in human tumors
INVENTOR(S): Vogelstein, Bert, Baltimore, MD, United States
Bigner, Darell, Mebane, NC, United States
PATENT ASSIGNEE(S): The Johns Hopkins Univiersity, Baltimore, MD, United States (U.S. corporation)
Duke University, Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5981725		19991109	<--
APPLICATION INFO.:	US 1995-479808		19950607	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-896909, filed on 11 Jun 1992 which is a continuation of Ser. No. US 1990-531410, filed on 1 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-404226, filed on 8 Sep 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 11
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 2161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 13 OF 14 USPATFULL on STN

ACCESSION NUMBER:	1999:99750 USPATFULL
TITLE:	Growth factor receptor antibodies
INVENTOR(S):	Wels, Winfried S., Emmendingen, Germany, Federal Republic of Schmidt, Mathias, Freiburg, Germany, Federal Republic of Vakalopoulou, Evangelia, Berlin, Germany, Federal Republic of Schneider, Douglas W, Lafayette, CA, United States
PATENT ASSIGNEE(S):	Schering Aktiengessellschaft, Berlin, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5942602		19990824	<--
APPLICATION INFO.:	US 1997-800198		19970213 (8)	

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Scheiner, Toni R.
LEGAL REPRESENTATIVE:	Millen, White, Zelano & Branigan, P.C.
NUMBER OF CLAIMS:	25
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT:	1184

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is related to single and double chain antibodies to EGF receptor. The invention also relates to toxin conjugates of such antibodies. These antibodies are useful for treating and diagnosing the status of pathological conditions such as **cancer** and cellular hyper proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 14 OF 14 USPATFULL on STN

ACCESSION NUMBER:	1999:43184 USPATFULL
TITLE:	Membrane-bound cytokine compositions comprising GM=**CSF** and methods of modulating an immune response using same
INVENTOR(S):	Hoo, William Soo, Carlsbad, CA, United States
PATENT ASSIGNEE(S):	The Immune Response Corporation, Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5891432		19990406	<--
APPLICATION INFO.:	US 1997-902516		19970729 (8)	

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Spector, Lorraine
LEGAL REPRESENTATIVE:	Campbell & Flores LLP
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1,13
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT:	1917

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody

immunomodulatory molecule such as GM-**CSF** operatively fused to a heterologous membrane attachment domain. Non-antibody immunomodulatory molecules useful in the invention include immunostimulatory and immunosuppressive molecules such as cytokines. In one embodiment, the invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain and, additionally, a disease-associated antigen or immunogenic epitope thereof. Further provided by the invention are methods of modulating an immune response against a disease-associated antigen by administering to an individual a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L Number	Hits	Search Text	DB	Time stamp
1	37	EGFRvIII same cancer	USPAT; US-PGPUB; EPO; DERWENT	2003/11/09 14:50
2	36	(EGFRvIII same cancer) and (urine or plasma or serum or csf)	USPAT; US-PGPUB; EPO; DERWENT	2003/11/09 14:50

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1641cxc

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  AUG 05   New pricing for EUROPATFULL and PCTFULL effective
                   August 1, 2003
 NEWS  5  AUG 13   Field Availability (/FA) field enhanced in BEILSTEIN
 NEWS  6  AUG 18   Data available for download as a PDF in RDISCLOSURE
 NEWS  7  AUG 18   Simultaneous left and right truncation added to PASCAL
 NEWS  8  AUG 18   FROSTI and KOSMET enhanced with Simultaneous Left and Righ
                   Truncation
 NEWS  9  AUG 18   Simultaneous left and right truncation added to ANABSTR
 NEWS 10  SEP 22   DIPPR file reloaded
 NEWS 11  SEP 25   INPADOC: Legal Status data to be reloaded
 NEWS 12  SEP 29   DISSABS now available on STN
 NEWS 13  OCT 10   PCTFULL: Two new display fields added
 NEWS 14  OCT 21   BIOSIS file reloaded and enhanced
 NEWS 15  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced

 NEWS EXPRESS  OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:52:46 ON 09 NOV 2003

=> file .jacob
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'CAPLUS' ENTERED AT 15:52:55 ON 09 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

```
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:52:55 ON 09 NOV 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 15:52:55 ON 09 NOV 2003

FILE 'EMBASE' ENTERED AT 15:52:55 ON 09 NOV 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'USPATFULL' ENTERED AT 15:52:55 ON 09 NOV 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> EGFRvIII(P)cancer
L1           34 FILE CAPLUS
L2           30 FILE BIOSIS
L3           31 FILE MEDLINE
L4           31 FILE EMBASE
L5           33 FILE USPATFULL

TOTAL FOR ALL FILES
L6          159 EGFRVIII(P) CANCER

=> dup rem
ENTER L# LIST OR (END):l1-l4
PROCESSING COMPLETED FOR L1
PROCESSING COMPLETED FOR L2
PROCESSING COMPLETED FOR L3
PROCESSING COMPLETED FOR L4
L7            51 DUP REM L1-L4 (75 DUPLICATES REMOVED)

=> l7 and (plasma or urine or csf or extract or sputum)
L8           34 S L7
L9            1 FILE CAPLUS
L10          12 S L7
L11           0 FILE BIOSIS
L12           3 S L7
L13           0 FILE MEDLINE
L14           2 S L7
L15           0 FILE EMBASE
L16           0 S L7
L17           0 FILE USPATFULL

TOTAL FOR ALL FILES
L18           1 L7 AND (PLASMA OR URINE OR CSF OR EXTRACT OR SPUTUM)

=> d l18 ibib abs total

L18  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2001:693382  CAPLUS
DOCUMENT NUMBER:          135:256132
TITLE:                    Sensitive detection of wild-type and mutant EGFR by
                          specific ELISA assays in any biological sample
INVENTOR(S):              Wong, Albert J.; Leitzel, Kim E.; Moscatello, David
                          K.; Lipton, Allan
PATENT ASSIGNEE(S):       Thomas Jefferson University, USA
SOURCE:                   PCT Int. Appl., 22 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

```
     PATENT NO.         KIND  DATE            APPLICATION NO.   DATE
     ---------------    ----  --------        ---------------   --------
     WO 2001068711       A1   20010920        WO 2001-US7766    20010312
         W:  CA, JP
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, TR
     US 2001046686       A1   20011129        US 2001-803854    20010312
     EP 1276771          A1   20030122        EP 2001-918548    20010312
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY, TR
PRIORITY APPLN. INFO.:                    US 2000-188424P   P  20000310
                                          WO 2001-US7766    W  20010312
AB   The present invention generally relates to a method of detecting type III
     mutant EGF receptor (EGFRvIII) in biol. samples, a method of
     detecting cancers and other diseases in biol. samples, and to a
     method of assessing treatment and selecting therapy for cancer
     patients.
REFERENCE COUNT:          7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> file .meeting
'EVENTLINE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    18.54       18.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                    -0.65       -0.65

FILE 'AGRICOLA' ENTERED AT 15:55:19 ON 09 NOV 2003

FILE 'BIOTECHNO' ENTERED AT 15:55:19 ON 09 NOV 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 15:55:19 ON 09 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 15:55:19 ON 09 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)


FILE 'IMSDRUGCONF' ENTERED AT 15:55:19 ON 09 NOV 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 15:55:19 ON 09 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)


FILE 'MEDICONF' ENTERED AT 15:55:19 ON 09 NOV 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 15:55:19 ON 09 NOV 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.
```

```
=> EGFRVIII(P) CANCER
L19           0 FILE AGRICOLA
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P) CANCER'
L20          40 FILE BIOTECHNO
L21           0 FILE CONFSCI
L22           0 FILE HEALSAFE
L23           0 FILE IMSDRUGCONF
L24          16 FILE LIFESCI
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P) CANCER'
L25           0 FILE MEDICONF
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P) CANCER'
L26          16 FILE PASCAL

TOTAL FOR ALL FILES
L27          72 EGFRVIII(P) CANCER

=> l27 and (plasma or urine or csf or extract or sputum)
L28           0 FILE AGRICOLA
L29           0 FILE BIOTECHNO
L30           0 FILE CONFSCI
L31           0 FILE HEALSAFE
L32           0 FILE IMSDRUGCONF
L33           0 FILE LIFESCI
L34           0 FILE MEDICONF
L35           0 FILE PASCAL

TOTAL FOR ALL FILES
L36           0 L27 AND (PLASMA OR URINE OR CSF OR EXTRACT OR SPUTUM)

=> l27 and (urine, plasma, csf, sputum, extract)
L37           0 FILE AGRICOLA
L38           0 FILE BIOTECHNO
L39           0 FILE CONFSCI
L40           0 FILE HEALSAFE
L41           0 FILE IMSDRUGCONF
L42           0 FILE LIFESCI
L43           0 FILE MEDICONF
L44           0 FILE PASCAL

TOTAL FOR ALL FILES
L45           0 L27 AND (URINE, PLASMA, CSF, SPUTUM, EXTRACT)

=> file .chemistry\
'.CHEMISTRY\' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'AGRICOLA, BIOTECHNO, CONFSCI, HEALSAFE, IMSDRUGCONF,
LIFESCI, MEDICONF, PASCAL'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file .chemistry
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               6.43      25.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -0.65

FILE 'CAPLUS' ENTERED AT 15:56:51 ON 09 NOV 2003
```

```
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 15:56:51 ON 09 NOV 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 15:56:51 ON 09 NOV 2003
Compendex Compilation and Indexing (C) 2003
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 15:56:51 ON 09 NOV 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 15:56:51 ON 09 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 15:56:51 ON 09 NOV 2003
COPYRIGHT (c) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 15:56:51 ON 09 NOV 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> EGFRvIII(P)(cancer or carcinoma or tumor)
L46          79 FILE CAPLUS
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)(CANCER'
L47          57 FILE BIOTECHNO
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)(CANCER'
L48           0 FILE COMPENDEX
L49           0 FILE ANABSTR
L50           0 FILE CERAB
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)(CANCER'
L51           0 FILE METADEX
L52          49 FILE USPATFULL

TOTAL FOR ALL FILES
L53         185 EGFRVIII(P)(CANCER OR CARCINOMA OR TUMOR)

=> l53 and (plasma or urine or csf or sputum)
L54           1 FILE CAPLUS
L55           0 FILE BIOTECHNO
L56           0 FILE COMPENDEX
L57           0 FILE ANABSTR
L58           0 FILE CERAB
L59           0 FILE METADEX
L60          35 FILE USPATFULL

TOTAL FOR ALL FILES
L61          36 L53 AND (PLASMA OR URINE OR CSF OR SPUTUM)

=> dup rem
ENTER L# LIST OR (END):161
PROCESSING COMPLETED FOR L61
L62           36 DUP REM L61 (0 DUPLICATES REMOVED)

=> d l54 ibib abs total

L54  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2001:693382  CAPLUS
DOCUMENT NUMBER:          135:256132
```

TITLE: Sensitive detection of wild-type and mutant EGFR by specific ELISA assays in any biological sample
INVENTOR(S): Wong, Albert J.; Leitzel, Kim E.; Moscatello, David K.; Lipton, Allan
PATENT ASSIGNEE(S): Thomas Jefferson University, USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068711	A1	20010920	WO 2001-US7766	20010312
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2001046686	A1	20011129	US 2001-803854	20010312
EP 1276771	A1	20030122	EP 2001-918548	20010312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				

PRIORITY APPLN. INFO.: US 2000-188424P P 20000310
WO 2001-US7766 W 20010312

AB The present invention generally relates to a method of detecting type III mutant EGF receptor (**EGFRvIII**) in biol. samples, a method of detecting **cancers** and other diseases in biol. samples, and to a method of assessing treatment and selecting therapy for **cancer** patients.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> l60 and (urine or plasma)
L63 1 FILE CAPLUS
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)(CANCER'
L64 0 FILE BIOTECHNO
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)(CANCER'
L65 0 FILE COMPENDEX
L66 0 FILE ANABSTR
L67 0 FILE CERAB
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)(CANCER'
L68 0 FILE METADEX
L69 27 FILE USPATFULL

TOTAL FOR ALL FILES
L70 28 L60 AND (URINE OR PLASMA)

=> l70 and py<2003
L71 1 FILE CAPLUS
L72 0 FILE BIOTECHNO
L73 0 FILE COMPENDEX
L74 0 FILE ANABSTR
L75 0 FILE CERAB
L76 0 FILE METADEX
L77 20 FILE USPATFULL

TOTAL FOR ALL FILES
L78 21 L70 AND PY<2003

=> l78 and ELISA

```
L79           1 FILE CAPLUS
L80           0 FILE BIOTECHNO
L81           0 FILE COMPENDEX
L82           0 FILE ANABSTR
L83           0 FILE CERAB
L84           0 FILE METADEX
L85          14 FILE USPATFULL

TOTAL FOR ALL FILES
L86          15 L78 AND ELISA

=> d l86 ibib abs total

L86  ANSWER 1 OF 15  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2001:693382  CAPLUS
DOCUMENT NUMBER:          135:256132
TITLE:                    Sensitive detection of wild-type and mutant EGFR by
                          specific ELISA assays in any biological
                          sample
INVENTOR(S):              Wong, Albert J.; Leitzel, Kim E.; Moscatello, David
                          K.; Lipton, Allan
PATENT ASSIGNEE(S):       Thomas Jefferson University, USA
SOURCE:                   PCT Int. Appl., 22 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.         KIND  DATE           APPLICATION NO.   DATE
     ---------------    ----  --------       ---------------   --------
     WO 2001068711       A1   20010920       WO 2001-US7766    20010312 <--
         W:  CA, JP
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, TR
     US 2001046686       A1   20011129       US 2001-803854    20010312 <--
     EP 1276771          A1   20030122       EP 2001-918548    20010312
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY, TR
PRIORITY APPLN. INFO.:                    US 2000-188424P  P  20000310
                                          WO 2001-US7766   W  20010312
AB   The present invention generally relates to a method of detecting type III
     mutant EGF receptor (EGFRvIII) in biol. samples, a method of
     detecting cancers and other diseases in biol. samples, and to a
     method of assessing treatment and selecting therapy for cancer
     patients.
REFERENCE COUNT:          7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L86  ANSWER 2 OF 15  USPATFULL on STN
ACCESSION NUMBER:         2002:297455  USPATFULL
TITLE:                    Methods and compositions for making dendritic cells
                          from expanded populations of monocytes and for
                          activating T cells
INVENTOR(S):              Nelson, Edward L., Eldersburg, MD, United States
                          Strobl, Susan L, Hagerstown, MD, United States
PATENT ASSIGNEE(S):       The United States of America as represented by the
                          Secretary of the Department of Health and Human
                          Services, Washington, DC, United States (U.S.
                          government)

                               NUMBER         KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 6479286          B1   20021112            <--
```

	WO 9853048	19991126	<--
APPLICATION INFO.:	US 2000-424173	20000605 (9)	
	WO 1999-US9810311	19990520	
		20000605 PCT 371 date	

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-47348P	19970521 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Ketter, James
ASSISTANT EXAMINER: Li, Q Janice
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of generating IL-3 expanded populations of monocytes and differentiating the cells into dendritic cells are provided. The methods include use of the dendritic cells to activate T-cells, in vitro and in vivo, and for ex vivo and other therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 3 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2002:254045 USPATFULL
TITLE: Molecular complexes which modify immune responses
INVENTOR(S): Schneck, Jonathan, Silver Spring, MD, United States
O'Herrin, Sean, Madison, WI, United States
Lebowitz, Michael S., Pikesville, MD, United States
Hamad, Abdel, Ellicott City, MD, United States
PATENT ASSIGNEE(S): The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6458354	B1	20021001	<--
APPLICATION INFO.:	US 2000-668143		20000925 (9)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-324782, filed on 3 Jun 1999 Continuation-in-part of Ser. No. US 1998-63276, filed on 21 Apr 1998, now patented, Pat. No. US 6140113 Continuation-in-part of Ser. No. US 1997-828712, filed on 28 Mar 1997

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-14367P	19960328 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 2579
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating

disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 4 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2002:246722 USPATFULL			
TITLE:	Structural alterations of the EGF receptor genes in human tumors			
INVENTOR(S):	Vogelstein, Bert, Baltimore, MD, United States Bigner, Darell, Mebane, NC, United States			
PATENT ASSIGNEE(S):	The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6455498	B1	20020924	<--
APPLICATION INFO.:	US 2000-664752		20000919 (9)	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-264723, filed on 9 Mar 1999, now patented, Pat. No. US 6127126 Division of Ser. No. US 1995-479808, filed on 7 Jun 1995, now patented, Pat. No. US 5981725 Continuation-in-part of Ser. No. US 1992-896909, filed on 11 Jun 1992, now abandoned Continuation of Ser. No. US 1990-531410, filed on 1 Jun 1990, now abandoned Continuation-in-part of Ser. No. US 1989-404226, filed on 8 Sep 1989, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Spector, Lorraine			
ASSISTANT EXAMINER:	Andres, Janet L.			
LEGAL REPRESENTATIVE:	Banner & Witcoff Ltd.			
NUMBER OF CLAIMS:	12			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	39 Drawing Figure(s); 30 Drawing Page(s)			
LINE COUNT:	2135			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 5 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2002:227904 USPATFULL			
TITLE:	In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells			
INVENTOR(S):	Zauderer, Maurice, Pittsford, NY, UNITED STATES Smith, Ernest S., Ontario, NY, UNITED STATES			
PATENT ASSIGNEE(S):	University of Rochester, Rochester, NY, 14642 (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002123057	A1	20020905	<--
APPLICATION INFO.:	US 2001-987456	A1	20011114 (9)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-249268P	20001117 (60)
	US 2001-262067P	20010118 (60)
	US 2001-271424P	20010227 (60)
	US 2001-298087P	20010615 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 83
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 7215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 6 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2002:191201 USPATFULL
TITLE: Uses of monoclonal antibody 8H9
INVENTOR(S): Cheung, Nai-Kong V., Purchase, NY, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002102264	A1	20020801	<--
APPLICATION INFO.:	US 2001-982645	A1	20011018 (9)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-241344P	20001018 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Albert Wai-Kit Chan, 141-07 20th Ave. Suite 604, Whitestone, NY, 11357
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 6128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 7 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2002:148255 USPATFULL

TITLE: Membrane-bound cytokine compositions and methods of modulating an immune response using same
INVENTOR(S): Hoo, William Soo, Carlsbad, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002076392	A1	20020620	<--
	US 6482407	B2	20021119	
APPLICATION INFO.:	US 2001-847185	A1	20010501 (9)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-201931, filed on 1 Dec 1998, PENDING Continuation of Ser. No. US 1997-902516, filed on 29 Jul 1997, GRANTED, Pat. No. US 5891432
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CAMPBELL & FLORES LLP, 4370 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN DIEGO, CA, 92122
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain. Non-antibody immunomodulatory molecules useful in the invention include immunostimulatory and immunosuppressive molecules such as cytokines. In one embodiment, the invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain and, additionally, a disease-associated antigen or immunogenic epitope thereof. Further provided by the invention are methods of modulating an immune response against a disease-associated antigen by administering to an individual a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 8 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2002:112301 USPATFULL
TITLE: Human anti-epidermal growth factor receptor single-chain antibodies
INVENTOR(S): Raisch, Kevin Paul, Birmingham, AL, UNITED STATES
Curiel, David T., Birmingham, AL, UNITED STATES
Bonner, James Alan, Vestavia Hills, AL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002058033	A1	20020516	<--
APPLICATION INFO.:	US 2001-976118	A1	20011012 (9)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240353P	20001013 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Benjamin Aaron Adler, ADLER & ASSOCIATES, 8011 Candle Lane, Houston, TX, 77071
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1063
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Human anti-epidermal growth factor receptor (EGFR) single-chain antibodies (scFvs) were isolated from a human IgM phage display library using purified epidermal growth factor receptor as antigen. Two isolates with different amino acid sequences were identified by **ELISA** as epidermal growth factor receptor-specific. The scFvs bind to the full length epidermal growth factor receptor and the truncated and/or mutated epidermal growth factor receptor on human cells. These anti-EGFR-scFvs are useful as therapeutic and/or diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 9 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2002:22438 USPATFULL			
TITLE:	Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses			
INVENTOR(S):	Paul, Sudhir, Houston, TX, UNITED STATES Gololobov, Gennady, Houston, TX, UNITED STATES Smith, Larry J., Omaha, NE, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002013274	A1	20020131	<--
APPLICATION INFO.:	US 2001-862849	A1	20010522 (9)	
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-46373, filed on 23 Mar 1998, GRANTED, Pat. No. US 6235714			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	DANN DORFMAN HERRELL & SKILLMAN, SUITE 720, 1601 MARKET STREET, PHILADELPHIA, PA, 19103-2307			
NUMBER OF CLAIMS:	13			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	15 Drawing Page(s)			
LINE COUNT:	3950			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens assocated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 10 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2001:218198 USPATFULL			
TITLE:	Sensitive detection of wild-type and mutant EGFR by specific **ELISA** assays in any biological sample			
INVENTOR(S):	Wong, Albert J., Philadelphia, PA, United States Leitzel, Kim E., Hummelstown, PA, United States Moscatello, David K., Philadelphia, PA, United States Lipton, Allan, Hershey, PA, United States			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001046686	A1	20011129	<--
APPLICATION INFO.:	US 2001-803854	A1	20010312 (9)	
	NUMBER	DATE		
PRIORITY INFORMATION:	US 2000-188424P	20000310 (60)		
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			

LEGAL REPRESENTATIVE: THOMAS JEFFERSON UNIVERSITY, INTELLECTUAL PROPERTY DIVISION, 1020 WALNUT STREET, SUITE 620, PHILADELPHIA, PA, 19107
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention generally relates a method of detecting type III mutant EGF receptor (**EGFRvIII**) in biological samples, a method of detecting **cancers** and other diseases in biological samples, and to a method of assessing treatment and selecting therapy for **cancer** patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 11 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2001:112055 USPATFULL
TITLE: Bifunctional molecules for delivery of therapeutics
INVENTOR(S): Davis, Pamela B., Cleveland heights, OH, United States
Ferkol, Jr., Thomas W., Concord, OH, United States
Eckman, Elizabeth, Ponte Vedra Beach, FL, United States
PATENT ASSIGNEE(S): Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6261787	B1	20010717	<--
APPLICATION INFO.:	US 1999-264032		19990308 (9)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-957333, filed on 24 Oct 1997, now patented, Pat. No. US 6072041
Continuation-in-part of Ser. No. US 1996-655705, filed on 3 Jun 1996, now patented, Pat. No. US 5972900
Continuation-in-part of Ser. No. US 1996-656906, filed on 3 Jun 1996, now patented, Pat. No. US 5972901
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Park, Hankyel T.
LEGAL REPRESENTATIVE: Banner & Witcoff LTD
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 1650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A bifunctional molecule consisting of a therapeutic molecule and a ligand which specifically binds a transcytotic receptor can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides the ability to deliver a therapeutic molecule directly to the apical surface of the epithelium, by targeting the transcytotic receptor with an appropriate ligand. Thus, the highest concentration of the therapeutic molecule will be at the apical surface, where it can have the greatest therapeutic effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 12 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2001:75367 USPATFULL
TITLE: Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
INVENTOR(S): Paul, Sudhir, 7900 Cambridge, 14-1G, Houston, TX, United States 77054
Gololobov, Gennady, 5500 N. Braeswood, Apt. 259, Houston, TX, United States 77096

Smith, Larry J., 7824 Jackson St., Omaha, NE, United States 68114

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6235714	B1	20010522	<--
APPLICATION INFO.:	US 1998-46373		19980323 (9)	

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huff, Sheela
LEGAL REPRESENTATIVE: Dann, Dorfman, Herrell and Skillman
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 3997
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens associated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 13 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2000:131598 USPATFULL
TITLE: Method for diagnosing glioma associated with structural alterations of the EGF receptor gene in human tumors
INVENTOR(S): Vogelstein, Bert, Baltimore, MD, United States
Bigner, Darell, Mebane, NC, United States
PATENT ASSIGNEE(S): The Johns Hopkins University, United States (U.S. corporation)
Duke University, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6127126		20001003	<--
APPLICATION INFO.:	US 1999-264723		19990309 (9)	

RELATED APPLN. INFO.: Division of Ser. No. US 1995-479808, filed on 7 Jun 1995, now patented, Pat. No. US 5981725 which is a continuation-in-part of Ser. No. US 1992-896909, filed on 11 Jun 1992, now abandoned which is a continuation of Ser. No. US 1990-531410, filed on 1 Jun 1990 which is a continuation-in-part of Ser. No. US 1989-404226, filed on 8 Sep 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Srivastava, Devah
LEGAL REPRESENTATIVE: Banner & Wifcoff, Ltd.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Figure(s); 30 Drawing Page(s)
LINE COUNT: 2152
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 14 OF 15 USPATFULL on STN

ACCESSION NUMBER: 1999:142132 USPATFULL
TITLE: Structural alterations of the EGF receptor gene in human tumors
INVENTOR(S): Vogelstein, Bert, Baltimore, MD, United States
Bigner, Darell, Mebane, NC, United States
PATENT ASSIGNEE(S): The Johns Hopkins Univiersity, Baltimore, MD, United States (U.S. corporation)
Duke University, Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5981725		19991109	<--
APPLICATION INFO.:	US 1995-479808		19950607 (8)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-896909, filed on 11 Jun 1992 which is a continuation of Ser. No. US 1990-531410, filed on 1 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-404226, filed on 8 Sep 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 11
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 2161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 15 OF 15 USPATFULL on STN
ACCESSION NUMBER: 1999:43184 USPATFULL
TITLE: Membrane-bound cytokine compositions comprising GM=**CSF** and methods of modulating an immune response using same
INVENTOR(S): Hoo, William Soo, Carlsbad, CA, United States
PATENT ASSIGNEE(S): The Immune Response Corporation, Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5891432		19990406	<--
APPLICATION INFO.:	US 1997-902516		19970729 (8)	

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spector, Lorraine
LEGAL REPRESENTATIVE: Campbell & Flores LLP
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1,13
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1917
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule such as GM-**CSF** operatively fused to a heterologous membrane attachment domain. Non-antibody immunomodulatory molecules useful in the invention include immunostimulatory and immunosuppressive molecules such as cytokines. In one embodiment, the invention provides a cellular vaccine having a membrane-bound fusion

protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain and, additionally, a disease-associated antigen or immunogenic epitope thereof. Further provided by the invention are methods of modulating an immune response against a disease-associated antigen by administering to an individual a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.